Topics
- Methods to risk stratify patients with HCM for SCD and role of AICD for primary prevention
- How to identify the phenotype of HCM and phenocopies that mimic HCM
- Benefits of cardiac transplantation in HCM and RCM and limitations of LVAD therapy in this population
- Surgical and interventional approaches to hypertrophic obstructive cardiomyopathy (HOCM)
- Emerging risk factors for SCD in HCM
- Mechanisms of specific disease modifying therapies for specific restrictive cardiomyopathies and their appropriate use
- Clinical utility and interpretation of genetic testing for patients with HCM and RCM
Who should Attend
Interventional cardiologists, adult and pediatric cardiologists, internists, pediatricians, physician assistants, cardiac nurses, physical therapists and other medical professionals involved in the evaluation, diagnosis and/or management of patients with hypertrophic and restrictive cardiomyopathy.
CME Credits: The College of Physicians and Surgeons designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
